Biblio

Found 6 results
Filters: Keyword is Injections, Spinal  [Clear All Filters]
2013
Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.
2011
Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.  2011.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.. J Neurosci Methods. 199(1):62-8.
2010
Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.  2010.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.. Br J Pharmacol. 161(5):986-1001.
Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.  2010.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.. Br J Pharmacol. 161(1):51-64.
2008
Tumati S, Milnes TLargent, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.  2008.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.. Eur J Pharmacol. 601(1-3):207-8.
Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.